This blog will provide information relating to newer biomedical technologies/research and health alternatives. All posted articles are not to be construed as an advice to apply, use, recommend, etc. Readers should carry out independent verification or consult a specialist. No liabilities whatsoever is accepted for any loss howsoever arising directly or indirectly as a result of actions taken on ideas and information found in this blog.
The *Preceyes system focuses on robotic assistance for vitreoretinal (VR)
surgeons. The system is designed to provide assistance so that the
surgeon can work with higher accuracy and precision, while at the same
time improving on dexterity. The system is expected to improve treatment
outcomes for patients and increase procedural safety, while the higher
degree of automation inherent to robotics is also expected to improve
clinical workflows and bring down costs.
The Preceyes robot is unique because of both its ultra-high-precision
and ultra-high-dexterity. This is achieved by scaling down movements in
the system, which dramatically increases precision by more than a factor
of 10, while also filtering out any surgeon hand tremor. The
instruments used in VR surgery are so fine that they often bend and
deform when inserted into the eye by hand—the level of control in our
system means this does not happen. The integration of the system with
the conventional operating room is also very sophisticated, and the
system can be used with the majority of operating tables.
Firstly there is patient access to surgery. The level of manual
control and precision that these VR surgeons have is incredible, but it
takes years and years of training to get to that level. Also, a VR
surgeon can quickly reach an age where hand tremor and other
inaccuracies can become a problem, often long before the normal
retirement age. So being able to use robotics to take over some of the
precision and dexterity allows us to train surgeons faster and extend
the number of years they can work once trained. This is, of course, an
even bigger issue in emerging economies, where there is currently a very
significant shortage of VR surgeons. But, given that the incidence of
VR diseases is expected to double in the next 15 years, there will also
soon be a shortage of VR surgeons in developed economies as well.
The other benefit is the improved accuracy and precision of the
surgery overall, which is expected to lead to dramatically improved
patient safety and health outcomes. This is a pattern that is true for
all robotic surgery. The ultra-high precision required in VR surgery
would suggest that the gains for patients from robotic assistance could
be even greater.
Finally, the technology opens up opportunities for totally new
therapies, particularly gene and cell therapies, vein cannulation, and
the possibility of sub-retinal implants. With the Preceyes system you
can place a needle in the sub-retinal space with a 10 micrometer
precision and keep it there for two or three minutes while you carefully
inject a fluid—that is something that is just impossible manually.
* Preceyes is currently undergoing first-in-human trials, which is a development stage.
Information on this page is provided for interest only on a "best efforts" basis and does not constitute personal advice. Always discuss medical conditions and related matters with your doctor.
Current methods of prostate cancer screening, such as prostate-specific antigen (PSA) tests and digital rectal exams (DRE), are somewhat unreliable and can lead to many uncertainties for both patient and urologist. Prostate biopsy, the most reliable method of detection, is a challenge because of the difficulties in visualizing not only the entirety of the prostate, but also the location of the biopsy needle. Trans-rectal ultrasound-guided prostate biopsy (TRUS), the current biopsy standard, commonly suffers from poor image resolution, and the biopsy needle often passes through tumor-free areas of the prostate - potentially missing the tumor entirely.
In addition, it can be difficult to distinguish between lesions that necessitate only a “watchful waiting” period and more aggressive lesions that require therapy. A more confident characterization of the type of lesion could help avoid the risk of side effects such as incontinence, impotence and bowel problems that can result from therapy. This is the current method of biospy and its drawbacks from random sampling:
To obtain prostate tissue for cancer testing, a series of
needles is poke (between 12 and 24) into different areas of the gland, guided by
ultrasound. This method was used since the 1980s. The ultrasound
images help to place the needles properly, but the pictures aren’t
distinct enough to be able to tell if it is cancerous from normal prostate
tissue, so there is no certainty of the target to home in on suspicious areas for biopsy. The truth is the current method is a scattershot “blind” approach in the hope that, if a
tumor is present, one of the needles will encounter it. These random
biopsies can miss some harmful tumors, while turning up others that are
inconsequential and may end up being treated unnecessarily.
The new Technology - Image Guided Prostrate Biopsy
An MRI scan is better than ultrasound at revealing details in soft
tissue in the case of the prostate gland. Prostate cancer cannot be diagnose
from an MRI image, but can certainly it can be used to identify suspicious
areas that warrant closer examination with a needle biopsy. The new fusion guided targeted biopsy technology combined the detailed MRI scans with live real-time ultrasound images of the prostate will enable a better diagnosis and outcome. Targeted MR/ultrasound biopsy is poised to become a new standard in prostate care. This technique fuses pre-biopsy MR images of the prostate with ultrasound-guided biopsy images in real time, for excellent delineaon of the prostate and suspicious lesions, as well as clear visualization of the biopsy needle.
The fusion of the MR and ultrasound images uses electromagnetic tracking, similar to your car’s GPS system. A small, localized electromagnetic field is generated and used in conjunction with a navigation sensor mounted to the trans-rectal ultrasound probe to determine the location and spatial orientation of the biopsy device. A sophisticated algorithm maintains the fusion of MR and ultrasound images even when the patient moves.
The Use of Uronav
A revolutionary new test can better pinpoint trouble spots and lead to a
quicker prostate cancer diagnosis. Invivo’s UroNav uses a combination
of MRI and Ultrasound. Unlike traditional biopsies that take twelve
samples, UroNav allows doctors to identify and remove only what looks
irregular. “Standard prostate biopsies are random and are systematically obtain random
samplings from the prostate. There’s no guarantee that a biopsy will
hit the cancer. For men who are moderate to high risk, UroNav can
cut down on random biopsies that may find nothing. It can also help to diagnose the cancer faster. The new technology, called UroNav, is like taking the blindfold off. The new UroNav technology that is being used utilizes the UroNav Fusion Biopsy System, and fuses (overlay) pre-biopsy MR images of the prostate with ultrasound-guided biopsy images in real time, for clear delineation of the prostate and suspicious lesions, as well as clear visualization of the biopsy needle.
Prostate cancer specialists at the University of Michigan Comprehensive Cancer Center (link is external)
are refining prostate cancer diagnosis to better identify those cancers
that are more likely to grow quickly and spread to other parts of the
body. The University of Michigan is the first in the region to offer men a new
technology that combines MRI and real-time ultrasound to help guide a
biopsy needle, ensuring that tissue from all suspicious areas is
captured. The fusion guided biopsy approach isn’t perfect. A recent study
found that the fusion method missed almost as many prostate tumors as
did standard biopsy. But as my Cleveland Clinic colleague, urologist J. Stephen Jones, MD, noted, the cancers that the fusion method missed were far more likely to be clinically insignificant ones. Put another way, fusion guided biopsy is better than the existing approach at finding prostate tumors we need to treat, while overlooking those we don’t need to worry about.
Each year in the United States, about 700,000 men with worrisome PSA
levels undergo repeat prostate biopsies. The fusion guided biopsy
approach should help reduce that number, by giving better
information the first time around. This tool should also be a boon to men who’ve been diagnosed with
small, slow-growing prostate tumors and who are on active surveillance –
also called watchful waiting – by possibly reducing the number of
biopsies they must undergo.
Information on this page is provided for interest only on a "best efforts" basis and does not constitute personal advice. Always discuss medical conditions and related matters with your doctor.
Like all types of dementia, Alzheimer's is
caused by brain cell death. It is a progressive neurodegenerative disease, which
means there is progressive brain cell death that happens over a course
of time. The total brain size shrinks with Alzheimer's - the tissue has
progressively fewer nerve cells and connections. A neurodegenerative type of dementia, the disease starts mild and gets progressively worse.
While they cannot be seen or tested in the living brain affected by
Alzheimer's disease, postmortem/autopsy will always show tiny inclusions
in the nerve tissue, called plaques and tangles:
Plaques are found between the dying cells in the brain - from the
build-up of a protein called beta-amyloid (you may hear the term
"amyloid plaques").
The tangles are within the brain neurons - from a disintegration of another protein, called tau.
The abnormal protein clumps, inclusions, in the brain tissue are always
present with the disease, but there could be another underlying process
that is actually causing the Alzheimer's - scientists are not yet sure.
This sort of change in brain nerves is also witnessed in other disorders,
and researchers want to find out more than just that there are protein
abnormalities - they also want to know how these develop so that a cure
or prevention might be discovered.
The most common presentation marking Alzheimer's dementia is where
symptoms of memory loss are the most prominent, especially in the area
of learning and recalling new information. But the initial presentation
can also be one of mainly language problems, in which case the greatest
symptom is struggling to find the right words.
If visuospatial deficits are most prominent, meanwhile, these would
include inability to recognize objects and faces, to comprehend separate
parts of a scene at once (simultanagnosia), and a type of difficulty
with reading text (alexia). Finally, the most prominent deficits in
"executive dysfunction" would be to do with reasoning, judgment and
problem-solving.
Symptoms of Alzheimer's Disease
1. Worsened ability to take in and remember new information, for example:
"Repetitive questions or conversations
Misplacing personal belongings
Forgetting events or appointments
Getting lost on a familiar route."
2. Impairments to reasoning, complex tasking, exercising judgment:
"Poor understanding of safety risks
Inability to manage finances
Poor decision-making ability
Inability to plan complex or sequential activities."
3. Impaired visuospatial abilities (but not, for example, due to eye sight problems):
"Inability to recognize faces or common objects or to find objects in direct view
Inability to operate simple implements, or orient clothing to the body."
4. Impaired speaking, reading and writing:
"Difficulty thinking of common words while speaking, hesitations
Speech, spelling, and writing errors."
5. Changes in personality and behavior, for example:
Out-of-character mood changes, including agitation; less interest, motivation or initiative; apathy; social withdrawal
Loss of empathy
Compulsive, obsessive or socially unacceptable behavior.
Stages of Alzheimer's Disease
The progression of Alzheimer's can be broken down into three basic stages:
Preclinical (no signs or symptoms yet)
Mild cognitive impairment
Dementia.
The Alzheimer's Association has broken this down further, describing
seven stages along a continuum of cognitive decline based on symptom
severity - from a state of no impairment, through mild and moderate
decline, and eventually reaching "very severe decline."
It is not usually until stage four that a diagnosis is clear - here it
is called mild or early-stage Alzheimer's disease, and "a careful
medical interview should be able to detect clear-cut symptoms in several
areas." Mild Alzheimer;s Disease (early stage) In the early stages of Alzheimer's, a person may function
independently. He or she may still drive, work and be part of social
activities. Despite this, the person may feel as if he or she is having
memory lapses, such as forgetting familiar words or the location of
everyday objects. Friends, family or neighbors begin to notice difficulties. During a
detailed medical interview, doctors may be able to detect problems in
memory or concentration. Common difficulties include:
Problems coming up with the right word or name
Trouble remembering names when introduced to new people
Having greater difficulty performing tasks in social or work settings
Forgetting material that one has just read
Losing or misplacing a valuable object
Increasing trouble with planning or organizing
Moderate Alzheimer's Disease (middle stage)
Moderate Alzheimer's is typically the longest stage and can last for
many years. As the disease progresses, the person with Alzheimer's will
require a greater level of care. You may notice the person with Alzheimer's confusing words, getting
frustrated or angry, or acting in unexpected ways, such as refusing to
bathe. Damage to nerve cells in the brain can make it difficult to
express thoughts and perform routine tasks. At this point, symptoms will be noticeable to others and may include:
Forgetfulness of events or about one's own personal history
Feeling moody or withdrawn, especially in socially or mentally challenging situations
Being unable to recall their own address or telephone number or the high school or college from which they graduated
Confusion about where they are or what day it is
The need for help choosing proper clothing for the season or the occasion
Trouble controlling bladder and bowels in some individuals
Changes in sleep patterns, such as sleeping during the day and becoming restless at night
An increased risk of wandering and becoming lost
Personality and behavioral changes, including suspiciousness and
delusions or compulsive, repetitive behavior like hand-wringing or
tissue shredding
Severe Alzheimer's Disease (late stage)
In the final stage of this disease, individuals lose the ability to
respond to their environment, to carry on a conversation and,
eventually, to control movement. They may still say words or phrases,
but communicating pain becomes difficult. As memory and cognitive skills
continue to worsen, personality changes may take place and individuals
need extensive help with daily activities. At this stage, individuals may:
Require full-time, around-the-clock assistance with daily personal care
Lose awareness of recent experiences as well as of their surroundings
Require high levels of assistance with daily activities and personal care
Experience changes in physical abilities, including the ability to walk, sit and, eventually, swallow
Have increasing difficulty communicating
Become vulnerable to infections, especially pneumonia
How common is Alzheimer's Disease?
In the US, the most recent census has enabled researchers to give estimates
of how many people have Alzheimer's disease. In 2010, some 4.7 million
people of 65 years of age and older were living with Alzheimer's disease
in the US.
The 2013 statistical report
from the Alzheimer's Association gives a proportion of the population
affected - just over a tenth of people in the over-65 age group have the
disease in the US. In the over-85s, the proportion goes up to about a
third.
Information on this page is provided for interest only on a "best efforts" basis and does not constitute personal advice. Always discuss medical conditions and related matters with your doctor.